| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
19,403 |
19,181 |
$3.15M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,184 |
4,133 |
$954K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,884 |
1,852 |
$577K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,383 |
1,352 |
$173K |
| 69436 |
Tympanostomy (requiring insertion of ventilating tube), general anesthesia |
141 |
141 |
$125K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
778 |
772 |
$72K |
| 36415 |
Collection of venous blood by venipuncture |
6,017 |
5,708 |
$57K |
| 80053 |
Comprehensive metabolic panel |
3,352 |
3,211 |
$55K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,478 |
3,196 |
$48K |
| 71045 |
Radiologic examination, chest; single view |
2,708 |
2,647 |
$47K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
326 |
323 |
$43K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
1,154 |
1,148 |
$42K |
| 87400 |
|
1,368 |
1,352 |
$39K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
463 |
461 |
$35K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
590 |
565 |
$31K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
223 |
222 |
$30K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,798 |
1,788 |
$25K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
629 |
606 |
$25K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
128 |
126 |
$22K |
| 83690 |
|
672 |
641 |
$18K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
897 |
892 |
$18K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
197 |
192 |
$17K |
| 70450 |
Computed tomography, head or brain; without contrast material |
277 |
274 |
$15K |
| 84484 |
|
976 |
857 |
$15K |
| 83880 |
|
379 |
368 |
$14K |
| 81003 |
|
1,641 |
1,613 |
$14K |
| 87430 |
|
841 |
829 |
$14K |
| 85610 |
|
703 |
673 |
$14K |
| 85027 |
|
1,454 |
1,422 |
$13K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
150 |
150 |
$13K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,256 |
1,218 |
$10K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
190 |
190 |
$9K |
| 87070 |
|
746 |
736 |
$7K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,776 |
1,464 |
$7K |
| 81001 |
|
2,303 |
2,132 |
$7K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
60 |
60 |
$6K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
747 |
710 |
$5K |
| 80179 |
|
318 |
303 |
$5K |
| 80143 |
|
318 |
303 |
$5K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
37 |
37 |
$5K |
| 81025 |
|
544 |
535 |
$4K |
| 83655 |
|
344 |
344 |
$4K |
| 73630 |
|
211 |
211 |
$4K |
| 73110 |
|
106 |
103 |
$3K |
| 87807 |
|
194 |
186 |
$2K |
| 71046 |
Radiologic examination, chest; 2 views |
92 |
92 |
$2K |
| 87420 |
|
99 |
99 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
27 |
24 |
$1K |
| 88304 |
|
27 |
27 |
$1K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
14 |
14 |
$1K |
| 85018 |
|
419 |
418 |
$819.01 |
| 73562 |
|
48 |
48 |
$783.43 |
| 81002 |
|
125 |
119 |
$372.09 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
32 |
32 |
$364.87 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
188 |
184 |
$268.64 |
| 85730 |
|
39 |
38 |
$187.25 |
| 87040 |
|
12 |
12 |
$184.04 |
| 87210 |
|
28 |
26 |
$137.11 |
| 86850 |
|
12 |
12 |
$104.28 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
12 |
12 |
$91.68 |
| 85379 |
|
13 |
12 |
$81.45 |
| 88720 |
|
16 |
12 |
$71.52 |
| 86900 |
|
12 |
12 |
$31.92 |
| 86901 |
|
12 |
12 |
$31.92 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
30 |
30 |
$2.41 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
13 |
13 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
12 |
12 |
$0.00 |